429 related articles for article (PubMed ID: 11073316)
21. Susceptibility to 5-aminolevulinic acid based photodynamic therapy in WHO I meningioma cells corresponds to ferrochelatase activity.
Hefti M; Holenstein F; Albert I; Looser H; Luginbuehl V
Photochem Photobiol; 2011; 87(1):235-41. PubMed ID: 21073472
[TBL] [Abstract][Full Text] [Related]
22. Protoporphyrin-IX distribution and photodynamic effect in rat oesophagus after aminolaevulinic acid administration.
Mäkinen K; Grönlund-Pakkanen S; Tiirikainen M; Nuutinen P; Kuusisto A; Alhava E
Scand J Gastroenterol; 1997 Jul; 32(7):633-7. PubMed ID: 9246700
[TBL] [Abstract][Full Text] [Related]
23. A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model.
Orenstein A; Kostenich G; Roitman L; Shechtman Y; Kopolovic Y; Ehrenberg B; Malik Z
Br J Cancer; 1996 Apr; 73(8):937-44. PubMed ID: 8611429
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms involved in delta-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin.
Ohgari Y; Nakayasu Y; Kitajima S; Sawamoto M; Mori H; Shimokawa O; Matsui H; Taketani S
Biochem Pharmacol; 2005 Dec; 71(1-2):42-9. PubMed ID: 16288996
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study.
Chang SC; MacRobert AJ; Porter JB; Bown SG
J Photochem Photobiol B; 1997 Apr; 38(2-3):114-22. PubMed ID: 9203372
[TBL] [Abstract][Full Text] [Related]
26. Influence of a haematoporphyrin derivative on the protoporphyrin IX synthesis and photodynamic effect after 5-aminolaevulinic acid sensitization in human colon carcinoma cells.
Messmann H; Geisler M; Gross U; Abels C; Szeimies RM; Steinbach P; Knüchel R; Doss M; Schölmerich J; Holstege A
Br J Cancer; 1997; 76(7):878-83. PubMed ID: 9328146
[TBL] [Abstract][Full Text] [Related]
27. Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro.
Krieg RC; Fickweiler S; Wolfbeis OS; Knuechel R
Photochem Photobiol; 2000 Aug; 72(2):226-33. PubMed ID: 10946577
[TBL] [Abstract][Full Text] [Related]
28. Metabolic characterization of tumor cell-specific protoporphyrin IX accumulation after exposure to 5-aminolevulinic acid in human colonic cells.
Krieg RC; Messmann H; Rauch J; Seeger S; Knuechel R
Photochem Photobiol; 2002 Nov; 76(5):518-25. PubMed ID: 12462647
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of cell death by 5-aminolevulinic acid-based photodynamic action and its enhancement by ferrochelatase inhibitors in human histiocytic lymphoma cell line U937.
Amo T; Kawanishi N; Uchida M; Fujita H; Oyanagi E; Utsumi T; Ogino T; Inoue K; Shuin T; Utsumi K; Sasaki J
Cell Biochem Funct; 2009 Dec; 27(8):503-15. PubMed ID: 19735078
[TBL] [Abstract][Full Text] [Related]
30. Photodynamic therapy using 5-aminolaevulinic acid for oesophageal adenocarcinoma associated with Barrett's metaplasia.
Tan WC; Fulljames C; Stone N; Dix AJ; Shepherd N; Roberts DJ; Brown SB; Krasner N; Barr H
J Photochem Photobiol B; 1999; 53(1-3):75-80. PubMed ID: 10672532
[TBL] [Abstract][Full Text] [Related]
31. The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy.
Choudry K; Brooke RC; Farrar W; Rhodes LE
Br J Dermatol; 2003 Jul; 149(1):124-30. PubMed ID: 12890205
[TBL] [Abstract][Full Text] [Related]
32. Iron chelation promotes 5-aminolaevulinic acid-based photodynamic therapy against oral tongue squamous cell carcinoma.
Qin J; Zhou C; Zhu M; Shi S; Zhang L; Zhao Y; Li C; Wang Y; Wang Y
Photodiagnosis Photodyn Ther; 2020 Sep; 31():101907. PubMed ID: 32619712
[TBL] [Abstract][Full Text] [Related]
33. Intraperitoneal photodynamic therapy in the Fischer 344 rat using 5-aminolevulinic acid and violet laser light: a toxicity study.
Major AL; Rose GS; Svaasand LO; Lüdicke F; Campana A; van Gemert MJ
J Photochem Photobiol B; 2002 Mar; 66(2):107-14. PubMed ID: 11897510
[TBL] [Abstract][Full Text] [Related]
34. Ferrochelatase Deficiency Abrogated the Enhancement of Aminolevulinic Acid-mediated Protoporphyrin IX by Iron Chelator Deferoxamine.
Palasuberniam P; Kraus D; Mansi M; Braun A; Howley R; Myers KA; Chen B
Photochem Photobiol; 2019 Jul; 95(4):1052-1059. PubMed ID: 30767226
[TBL] [Abstract][Full Text] [Related]
35. PDT effects of m-THPC and ALA, phototoxicity and apoptosis.
Bourré L; Rousset N; Thibaut S; Eléouet S; Lajat Y; Patrice T
Apoptosis; 2002 Jun; 7(3):221-30. PubMed ID: 11997666
[TBL] [Abstract][Full Text] [Related]
36. Experimental investigation of a combinational iron chelating protoporphyrin IX prodrug for fluorescence detection and photodynamic therapy.
Magnussen A; Reburn C; Perry A; Wood M; Curnow A
Lasers Med Sci; 2022 Mar; 37(2):1155-1166. PubMed ID: 34218351
[TBL] [Abstract][Full Text] [Related]
37. Evidence for a bystander role of neutrophils in the response to systemic 5-aminolevulinic acid-based photodynamic therapy.
de Bruijn HS; Sluiter W; van der Ploeg-van den Heuvel A; Sterenborg HJ; Robinson DJ
Photodermatol Photoimmunol Photomed; 2006 Oct; 22(5):238-46. PubMed ID: 16948825
[TBL] [Abstract][Full Text] [Related]
38. Small molecule kinase inhibitors enhance aminolevulinic acid-mediated protoporphyrin IX fluorescence and PDT response in triple negative breast cancer cell lines.
Palasuberniam P; Kraus D; Mansi M; Howley R; Braun A; Myers K; Chen B
J Biomed Opt; 2021 Sep; 26(9):. PubMed ID: 34545713
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of photodynamic therapy in gastric cancer cells by removal of iron.
Tan WC; Krasner N; O'Toole P; Lombard M
Gut; 1997 Jul; 41(1):14-8. PubMed ID: 9274465
[TBL] [Abstract][Full Text] [Related]
40. Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma.
Inoue K; Fukuhara H; Kurabayashi A; Furihata M; Tsuda M; Nagakawa K; Fujita H; Utsumi K; Shuin T
Cancer Sci; 2013 Jun; 104(6):765-72. PubMed ID: 23480042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
